Molecular Classification
Enzyme, Phosphotransferase
Other Names
ADK, myokinase, ATP-AMP phosphotransferase, EC 2.7.4.3, Nucleoside monophosphate kinase, Adenylkinase
Disease Roles
CancerCardiovascular disease (e.g., ischemia, myocardial injury)Hemolytic anemia

Adenylate kinase Overview

Adenylate kinase is a highly conserved phosphotransferase enzyme (EC 2.7.4.3) present in all known organisms and tissues[2][3][8]. It catalyzes the reversible transfer of phosphate groups among adenine nucleotides, specifically the interconversion of ATP, ADP, and AMP (2 ADP ⇌ ATP + AMP), which is critical for maintaining cellular energy balance[1][3][8][10]. The enzyme consists of distinct domains for binding nucleotides and undergoes significant conformational changes during catalysis[1][5]. Multiple isoforms are found in humans, with tissue- and compartment-specific functions[2]. Adenylate kinase is involved in regulating nucleotide pools, supports various cellular signaling pathways, interacts with other metabolic enzymes and protein complexes, and impacts physiological processes such as cell maturation, apoptosis, and response to metabolic stress[2][3][9]. Its dysfunction has been linked to cardiovascular disease, cancer, and certain genetic disorders, supporting its emerging role as a therapeutic target and a marker for disease diagnosis or prognosis[2][9].

Mechanism of Action

Inhibition of adenylate kinase activity blocks the conversion/interconversion of AMP, ADP, and ATP, thereby disrupting nucleotide balance and cellular energy charge[8][9].

Biological Functions

Cellular energy metabolism
Nucleotide homeostasis
Signal transduction
Regulation of cell differentiation
Apoptosis
Oncogenesis
Cell proliferation

Disease Associations

Cancer
Cardiovascular disease (e.g., ischemia, myocardial injury)
Hemolytic anemia
Aleukocytosis
Primary ciliary dyskinesia
Metabolic disorders

Safety Considerations

  • Essential for basic energy homeostasis, so inhibition leads to widespread bioenergetic disruption and potentially cytotoxicity.
  • Non-isoform-selective targeting risks affecting multiple tissues and cell types.

Interacting Drugs

Ap5A (P^1^,P^5^-di(adenosine-5') pentaphosphate, an inhibitor used experimentally)[4][5]
No widely approved clinical drugs target adenylate kinase directly; however, several inhibitors and probes are used in research.

Associated Biomarkers

Biomarker
Adenylate kinase isoenzyme levels may serve as biomarkers in diseases such as myocardial infarction, certain hemolytic anemias, and metabolic stress[2][9].